How does cannabis-induced psychosis differ from schizophrenia?

Cannabis-using patients with psychosis showed higher scores in pressure of speech, distractible speech, and clanging. Schizophrenia patients without cannabis use showed higher scores in derailment, incoherence, illogicality, and global rating of positive formal thought disorder. Both groups had significantly higher neurological soft sign scores than healthy controls.

Cross-sectional hospital-based study comparing 50 cannabis-using patients with psychosis (DSM-5 CUD) to 50 age-matched schizophrenia patients without cannabis use, plus 30 healthy controls. Psychotic symptoms assessed using the Scale for Assessment of Positive Symptoms.

Distinguishing cannabis-induced psychosis from schizophrenia has important treatment implications. If the symptom profiles are genuinely different, clinicians may be able to better identify when psychosis is substance-driven versus a primary psychiatric disorder.

The finding that cannabis-induced psychosis has distinct clinical features supports treating it as a separate diagnostic entity. However, some individuals with cannabis-induced psychosis eventually develop schizophrenia, making the boundary between these conditions less clear-cut than symptom profiles alone might suggest.

Relatively small sample from a single hospital. Cross-sectional design cannot determine whether cannabis-induced psychosis represents a distinct disorder or an early manifestation of schizophrenia. Indian population may limit generalizability.